Please assess the completion status of the following clinical trial:

Trial Title: The Influence of Nonspecific Immunostimulation on Changes in the Concentration of iNKT Cells

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Children of both genders aged 5 to 17 years.~* Children with grass pollen-induced allergic rhinitis recognized and treated according to current ARIA (Allergic Rhinitis and its Impact on Asthma) recommendations.~* Positive skin prick test to grass pollen allergens or positive specific IgE (defined as ≥ class 2, ≥ 0,70 kU/l) against timothy grass pollen allergens.~* Presentation of clinical symptoms of the allergic rhinitis (rhinorrhea, nasal congestion, nasal itching, sneezing) in at least two recent grass pollen seasons in Poland before inclusion in the study.~* Proper use of polyvalent mechanical bacterial lysate sublingual tablets.~* Not using drugs to alleviate the symptoms of allergic rhinitis in the last 7 days prior to enrollment in the study: intranasal glucocorticosteroids, intranasal, oral and ophthalmic antihistamines, intranasal and oral alpha-mimetics, intranasal anticholinergics, antileukotrienes and cromones.~* Written informed consent obtained from parents/guardians before any study related procedures are performed.~Exclusion Criteria:~* Patient received mechanical bacterial lysate immunostimulation within the previous 12 months before randomisation visit.~* Patient received chemical bacterial lysate immunostimulation within the previous 6 months before randomisation visit.~* Patient received oral/subcutaneous allergen-immunotherapy within the previous 3 years before the start of the study.~* Other chronic conditions of the nose or nasal sinuses.~* Severe nasal septum deviation.~* Acute respiratory infection in the 2 weeks prior to randomization visit.~* Treatment with systemic corticosteroids within the last 6 months before the start of the study.~* History of transfusion of blood, blood components or blood products.~* Pregnant or breastfeeding woman.~* Other chronic, uncontrolled diseases of the respiratory tract, gastrointestinal tract, urinary system, hematological diseases, immunodeficiency, cancer, cystic fibrosis.

- Gender: ALL
- Minimum Age: 5 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- Polyvalent mechanical bacterial lysate (Type: EXPERIMENTAL): Treatment over 3 successive months with one daily sublingual tablet (7 mg of bacterial lysate) over 10 days followed by 20 days of rest.
- Placebo (Type: PLACEBO_COMPARATOR): Treatment over 3 successive months with one daily sublingual tablet over 10 days followed by 20 days of rest.

Based on this trial design, predict the completion outcome and termination type (if applicable).